U.K. (FTSE) Biotech Industry Analysis

Industry Valuation and Performance

Has the U.K. Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 18 Aug 2026	UK£3.1b	UK£895.0m	-UK£151,773,527.36	17.8x	-20.4x	3.5x
Thu, 16 Jul 2026	UK£3.3b	UK£895.0m	-UK£151,828,363.20	18.4x	-21.5x	3.7x
Sat, 13 Jun 2026	UK£3.3b	UK£893.6m	-UK£152,920,721.65	18.4x	-21.4x	3.7x
Mon, 11 May 2026	UK£3.1b	UK£888.4m	-UK£111,894,338.90	19.3x	-27.5x	3.5x
Wed, 08 Apr 2026	UK£3.0b	UK£893.2m	UK£3.0m	9.6x	1016.5x	3.4x
Fri, 06 Mar 2026	UK£3.3b	UK£875.5m	-UK£4,226,098.16	9.3x	-777.8x	3.8x
Sun, 01 Feb 2026	UK£3.9b	UK£876.0m	-UK£28,951,001.78	10.7x	-134.2x	4.4x
Tue, 30 Dec 2025	UK£3.2b	UK£896.7m	-UK£29,534,812.78	10.3x	-109.6x	3.6x
Thu, 27 Nov 2025	UK£3.2b	UK£895.3m	-UK£30,726,141.50	10.8x	-103.7x	3.6x
Sat, 25 Oct 2025	UK£3.2b	UK£879.0m	-UK£44,262,370.25	15.5x	-72.8x	3.7x
Mon, 22 Sep 2025	UK£3.4b	UK£857.6m	-UK£83,268,050.87	16.2x	-40.5x	3.9x
Wed, 20 Aug 2025	UK£3.3b	UK£854.5m	-UK£103,302,225.72	12.1x	-32x	3.9x
Fri, 18 Jul 2025	UK£2.9b	UK£854.7m	-UK£103,117,559.27	13.3x	-28.1x	3.4x
Sun, 15 Jun 2025	UK£2.6b	UK£857.1m	-UK£104,134,043.00	13.4x	-24.7x	3x
Tue, 13 May 2025	UK£2.4b	UK£879.8m	-UK£94,920,497.94	13.1x	-25.7x	2.8x
Thu, 10 Apr 2025	UK£1.9b	UK£877.4m	-UK£179,173,860.72	16.5x	-10.8x	2.2x
Sat, 08 Mar 2025	UK£2.4b	UK£843.8m	-UK£278,120,667.47	18x	-8.6x	2.8x
Mon, 03 Feb 2025	UK£2.8b	UK£842.2m	-UK£295,621,545.33	90.8x	-9.5x	3.3x
Wed, 01 Jan 2025	UK£2.6b	UK£841.9m	-UK£294,651,079.12	74.7x	-8.8x	3.1x
Fri, 29 Nov 2024	UK£2.7b	UK£840.9m	-UK£294,063,299.25	83.7x	-9.3x	3.2x
Sun, 27 Oct 2024	UK£3.0b	UK£840.2m	-UK£291,990,901.67	96.8x	-10.1x	3.5x
Tue, 24 Sep 2024	UK£2.8b	UK£831.9m	-UK£310,148,019.90	88.2x	-8.9x	3.3x
Thu, 22 Aug 2024	UK£2.6b	UK£836.7m	-UK£250,657,127.76	30.5x	-10.5x	3.2x
Sat, 20 Jul 2024	UK£2.6b	UK£837.9m	-UK£257,011,839.28	28.8x	-10x	3.1x
Mon, 17 Jun 2024	UK£2.6b	UK£835.7m	-UK£273,377,481.57	29.4x	-9.6x	3.1x
Wed, 15 May 2024	UK£3.0b	UK£835.8m	-UK£289,527,504.00	31.4x	-10.3x	3.6x
Fri, 12 Apr 2024	UK£3.1b	UK£902.6m	-UK£201,201,901.13	29.1x	-15.4x	3.4x
Sun, 10 Mar 2024	UK£3.1b	UK£897.4m	-UK£203,115,454.35	34.5x	-15.4x	3.5x
Tue, 06 Feb 2024	UK£3.4b	UK£913.6m	-UK£198,350,507.55	31.6x	-17.3x	3.7x
Thu, 04 Jan 2024	UK£6.4b	UK£1.3b	-UK£245,548,389.00	37.5x	-25.9x	5x
Sat, 02 Dec 2023	UK£6.1b	UK£1.3b	-UK£245,388,294.00	35.5x	-24.8x	4.8x
Mon, 30 Oct 2023	UK£6.4b	UK£1.3b	-UK£253,173,371.00	36.9x	-25.1x	5x
Wed, 27 Sep 2023	UK£6.5b	UK£1.3b	-UK£223,681,158.00	23.6x	-29.2x	5.1x
Fri, 25 Aug 2023	UK£6.6b	UK£1.3b	-UK£208,325,400.00	23.6x	-31.8x	5.3x

Current Industry PE

Investors are relatively neutral on the British Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PS ratio of 3.7x.

Past Earnings Growth

The earnings for companies in the Biotechs industry have improved over the last three years.
Meanwhile revenues for these companies have declined 11% per year.
This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?


GB Market	-1.36%
Healthcare	-3.49%
Biotech	-1.08%
Biotech	-1.08%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
AVCT Avacta Group	UK£0.66	2.2% +UK£6.6m	32.3%	PS2715.1x
OXB Oxford Biomedica	UK£4.92	1.0% +UK£6.1m	-2.6%	PS3.5x
0KF3 Palatin Technologies	US$10.70	45.4% +US$5.9m	55.5%	PS1.5x
BVXP Bioventix	UK£15.75	5.0% +UK£3.9m	-34.4%	PE11.1x
SVNS Solvonis Therapeutics	UK£0.0015	11.1% +UK£1.0m	-50.8%	PB1.6x

Solvonis Therapeutics Advances SVN-015 Into Further NIDA-Funded Studies Following Encouraging Initial Screening

Solvonis Therapeutics plc announced encouraging results from the initial in vitro cardiac ion-channel and broader off-target screening of SVN-015 under the U.S. National Institute on Drug Abuse's Addiction Treatment Discovery Program. The Company previously announced SVN-015's acceptance into the ATDP in December 2025. Following review of the initial screening results, NIDA has confirmed that SVN-015 will advance into further evaluation under the ATDP. This is expected to include confirmatory transporter studies and in vivo studies to characterise the onset and duration of its pharmacological activity. SVN-015 is a proprietary discovery-stage small molecule designed to modulate key monoamine transporters, including the dopamine transporter and serotonin transporter. It is being developed initially as a potential treatment for stimulant use disorder, including cocaine and methamphetamine use disorders. The initial NIDA evaluation was designed to identify potential cardiac ion-channel and broader off-target liabilities before SVN-015 progressed into more extensive preclinical pharmacological studies. SVN-015 completed the initial cardiac ion-channel screening and demonstrated an encouraging broader off-target profile. The results were sufficiently encouraging for NIDA to progress the compound into further evaluation. On the cardiac ion-channel measures assessed to date, SVN-015 demonstrated a more favourable profile than GBR-12909, an earlier dopamine transporter inhibitor evaluated by NIDA as a potential treatment for cocaine dependence and known to interact with several cardiac ion channels. These preliminary preclinical findings do not establish the safety of SVN-015 in humans or whole animals. Further safety pharmacology, toxicology and clinical evaluation will be required as the programme progresses. The next stage of the NIDA programme is expected to further characterise SVN-015's intended transporter pharmacology, off-target profile and activity in vivo. The planned work is expected to include in vivo mouse locomotor-activity time-course study to characterise the onset and duration of SVN-015's pharmacological effects, confirmatory DAT binding and functional studies, and follow-up assessment of activity at the 5-HT2B receptor. These studies will be funded and undertaken through NIDA's preclinical ATDP. This support provides Solvonis with access to NIDA-funded specialist research capabilities rather than a grant payment to the Company. Solvonis retains ownership of SVN-015 and its associated intellectual property. Successful completion of this stage would provide Solvonis with an important preclinical data package to inform the compound's future development strategy and could support applications for additional non-dilutive NIH or NIDA development funding. There is currently no FDA-approved medication for stimulant use disorder, including cocaine and methamphetamine use disorders. Existing treatment is primarily based on behavioural interventions, leaving a significant unmet need for effective pharmacological treatment options. SVN-015 emerged from Solvonis' proprietary, AI-enabled CNS discovery programme. Composition-of-matter patent applications have been filed to protect the compound and related intellectual property.

U.K. (FTSE) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Forecast breakeven date pushed back to 2028

New minor risk - Financial data availability

CRISM Therapeutics Corporation Completes Site Initiation Visit for Phase II Study of Irinotecan Chemoseed

Arecor Therapeutics plc Publishes Clinical Data for AT278 in Peer-Reviewed Journal

Solvonis Therapeutics Advances SVN-015 Into Further NIDA-Funded Studies Following Encouraging Initial Screening

Consensus EPS estimates increase by 19%

Faron Pharmaceuticals Oy Announces Encouraging First Overall Survival Data from Frontline Higher-Risk Mds Patients in the Bexmab Phase 1/2 Trial

An asymmetric deep-value biotech incubator trapped in a severe conglomerate discount despite recurring proof of multi-billion dollar asset.

Aptamer Group PLC Provides Earnings Guidance for the Fiscal Year 2026

Avacta Group plc Announces Appointment of Patrick Vink as Non-Executive Deputy Chairman and Senior Independent Director

SkinBioTherapeutics plc Announces Termination of Emily Lorraine Bertram as Director, Effective June 30, 2026

Palatin Technologies, Inc., Annual General Meeting, Jul 28, 2026

Investor sentiment improves as stock rises 18%

4basebio PLC Appoints Jeff Coller to Strategic Advisory Board

Hemogenyx Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2026

Genflow Biosciences plc, Annual General Meeting, Jun 29, 2026